[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemic-cardiovascular-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemic-cardiovascular-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100604453","temporary-mcs-with-the-ivac-2l-transaortic-device-in-high-risk-pci-100604453",false,"NCT07149714","Temporary MCS With the iVAC 2L Transaortic Device in High-risk PCI","Temporary Mechanical Circulatory Support With the iVAC 2L Transaortic Device in High-risk Percutaneous Coronary Intervention","POTOK","Inclusion Criteria:\n\n* Multidisciplinary heart team consensus for high-risk PCI. HR-PCI was defined as any percutaneous intervention for coronary disease involving an unusually high risk of periprocedural circulatory collapse.\n* Signed Informed Consent to participate in the study\n\nExclusion Criteria:\n\n* Femoral artery diameter \\\u003C 6.0mm\n* Significant biventricular or right heart failure\n* Thrombus in the left ventricle\n* Presence of a mechanical aortic valve\n* Aortic valve stenosis\u002Fcalcification (equivalent to an orifice area of 0.6 cm2 or less) or moderate-to-severe aortic insufficiency (echocardiographic assessment graded as ≥+2)\n* Severe peripheral arterial disease precluding placement of the iVAC2L\n* Combined cardiorespiratory failure\n* Presence of an atrial or ventricular septal defect (including post infarct VSD)\n* Left ventricular rupture\n* Cardiac tamponade\n* Presence of any other subtype of shock\n* Known severe comorbidities independently affecting prognosis (chronic renal or liver failure, active malignancies etc.)\n* Recent major bleeding event (\\\u003C 3 months)\n* Recent stroke (\\\u003C 3 months)","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","Patients with coronary artery disease and undergoing high-risk percutaneous coronary intervention (PCI) are at increased risk of hemodynamic instability and poor outcomes. Mechanical circulatory support (MCS) devices may offer hemodynamic stabilization during PCI, potentially improving short- and long-term outcomes. The study rationale is to investigate the safety and clinical efficacy of temporary MCS with the iVAC 2L transaortic device in high-risk percutaneous coronary intervention.\n\nThe transaortic system for short-term circulatory support with pulsatile blood flow iVAC 2L consists of an external membrane pump, a 17Fr diameter catheter for reversed blood flow (intake cannula) with a patented two-way rotary valve.\n\nThe pump has two chambers, one for blood and one for helium, separated by a flexible diaphragm. The blood chamber connects to the catheter and the air chamber connects to a standard IABP console. The bi-directional valve is located 72 mm from the aspiration tip of the catheter and determines the direction of blood flow. The catheter is advanced retrogradely through the common femoral artery so that the tip is located in the left ventricular (LV) cavity and the valve is in the ascending aorta. Synchronized with the cardiac cycle via ECG, the device draws blood from the LV into the pump chamber during systole and ejects blood from the pump into the ascending aorta during diastole.\n\nThe primary composite outcome is all-cause mortality, including acute myocardial infarction, stroke and TIA during hospitalization and at Day 360 of follow-up, expressed as a percentage of total patients.",[27,28,29,30,31,32,33],"Ischemic Cardiovascular Disease","Multivessel Coronary Artery Disease","Coronary Artery Disease","Cardiogenic Shock","Acute Heart Failure (AHF)","Chronic Heart Failure","Percutaneous Coronary Intervention",[35,36,37],"Mechanical circulatory support","High-Risk Percutaneous Coronary Intervention","Coronary artery disease","RECRUITING","2025-08-29",{"date":41,"type":42},"2025-09-08","ACTUAL",{"date":44,"type":42},"2023-02-17",{"date":46,"type":21},"2029-02-17",{"name":48,"class":49},"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","OTHER_GOV",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":50},"100599748","phase-4-traditional-chinese-medicine-intervention-for-ischemic-cardiovascular-disease-comorbid-with-diabetes-mellitus-an-efficacy-comparative-study-100599748","NCT07088523","Traditional Chinese Medicine Intervention for Ischemic Cardiovascular Disease Comorbid With Diabetes Mellitus: An Efficacy Comparative Study","TICDEs","Inclusion Criteria:\n\n* Age\\>18 years;\n* Met the diagnostic criteria for myocardial infarction and type 2 diabetes mellitus;\n* Within 72 hours of myocardial infarction onset;\n* Met the diagnostic criteria of \"toxins damaging collaterals\"；\n* Voluntary participation in the study with consent forms signed.\n\nExclusion Criteria:\n\n* Long-term (\\>20 min) cardio-pulmonary resuscitation (CPR);\n* Critical illness due to STEMI (such as serious cardiogenic shock, uncontrolled acute left heart failure or pulmonary edema, malignant arrhythmias, explicit mechanical complications, etc. );\n* Suspected aortic dissection or acute pulmonary embolism;\n* Bleeding history in any organ system within 1 month, or presence of active hemorrhage at any part of the body, or known hemorrhagic constitution, or severe coagulation disorder or current usage of anticoagulants;\n* Uncontrolled severe diabetic ketoacidosis;\n* Serious hepatic dysfunction or serious renal dysfunction ( ALT\u002FAST≥3 ULN or eGFR\\\u003C30mL\u002Fmin\u002F1.73 m2 or equiring dialysis );\n* Serious COPD or respiratory failure;\n* Severe infection (such as positive blood cultures, septic shock, and septic pneumonia, etc.);\n* Neuropsychiatric system diseases or unconscious and unable to cooperate with examination and treatment;\n* Malignancies or other conditions with expected survival time\\\u003C1 year or unsuitability to participate in this study due to other diseases;\n* Allergy to the ingredients of the research drugs;\n* Women who are in pregnancy or nursery;\n* Participation in clinical trial of other traditional Chinese medicine.","80 Years",{"count":60,"type":21},4205,[62],"PHASE4","The population with comorbid ischemic cardiovascular disease (ICD) and diabetes mellitus (DM) has been growing rapidly, characterized by high mortality rates and frequent vascular event recurrence. DM exacerbates ischemic heart disease incidence and significantly elevates mortality in this comorbid population. Polypharmacy in these patients increases risks of adverse drug interactions and imposes substantial healthcare burdens. The pathological mechanisms of comorbidity demonstrate significant alignment with the TCM. Experimental studies indicate that Xintong Oral Liquid can ameliorate myocardial ischemia through multiple mechanisms to improve vascular endothelial function and microvascular dysfunction. This study aims to investigate the long-term effects of TCM intervention in patients with comorbid ICD and DM within 72 hours of symptom onset, and to evaluate whether the TCM treatment approach-centered on Xintong Oral Liquid within an integrated general treatment and syndrome differentiation framework-demonstrates superiority over control therapy in reducing 90-day major adverse cardiovascular and cerebrovascular events (MACCEs).",[65,27],"Diabete Mellitus",[65,67,68,69],"Ischemic cardiovascular disease","real-world","Xintong Oral Liquid","NOT_YET_RECRUITING","2025-07-20",{"date":73,"type":42},"2025-07-28",{"date":75,"type":21},"2025-07-31",{"date":77,"type":21},"2027-12-31",{"name":79,"class":80},"Guangzhou University of Traditional Chinese Medicine","OTHER",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":50},"100583505","multicenter-randomised-prospective-study-for-external-support-mesh-vest-of-venous-coronary-grafts-on-the-right-territory-100583505","NCT06877195","Multicenter Randomised Prospective Study for External Support Mesh VEST of Venous Coronary Grafts on the Right Territory","Multicenter Randomised Prospective Study for External Support Mesh VEST of Venous Coronary Grafts on the Right Territory: Mid-term Clinically Driven Re-rivascularization Events Comparison Between Sites Treated With VEST, Sites Treated With Bare Vein, Sites Treated With Other Conduits and de Novo Lesions on the Native Vessels","RiVEST","Inclusion Criteria:\n\n* combined or isolated interventions\n* adequate vein calibre\n* adequate graft flowmetry\n\nExclusion Criteria:\n\n* inability to implant due to calibre disparity or inadequate flowmetry",{"count":90,"type":21},300,[24],"Multicentre randomised prospective study aimed at verifying medium-term patency of venous grafts on the right coronary artery territory, by clinical and\u002For instrumental follow-up with particular attention to clinically driven re-revascularisation events regarding the site of new lesions (granularly comparing sites already treated with VEST, sites treated with bare vein, sites treated with other conduits, de novo lesions on the native).",[27],[95],"Coronary Artery Bypass Graft","2025-03-14",{"date":98,"type":42},"2025-03-18",{"date":100,"type":42},"2025-03-01",{"date":102,"type":21},"2028-05-01",{"name":104,"class":80},"Cardiochirurgia E.H."]